Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor. - Wikidata - wikimedia - TriplyDB

Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor.

Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor.

http://www.wikidata.org/entity/Q34329186

about

The Application of Natural Killer Cell Immunotherapy for the Treatment of Cancer Beyond CD19: Opportunities for Future Development of Targeted Immunotherapy in Pediatric Relapsed-Refractory Acute Leukemia Adoptive immunotherapy for acute leukemia: New insights in chimeric antigen receptors Recognition and killing of cancer stem-like cell population in hepatocellular carcinoma cells by cytokine-induced killer cells via NKG2d-ligands recognition Novel therapeutic options in Acute Myeloid Leukemia Novel Prognostic and Therapeutic Mutations in Acute Myeloid Leukemia In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid Leukemia Translating leukemia stem cells into the clinical setting: Harmonizing the heterogeneity.AntiCD3Fv fused to human interleukin-3 deletion variant redirected T cells against human acute myeloid leukemic stem cells Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients.Engineered T cells for cancer treatment 5T4-specific chimeric antigen receptor modification promotes the immune efficacy of cytokine-induced killer cells against nasopharyngeal carcinoma stem cell-like cells.miR-125a regulates cell cycle, proliferation, and apoptosis by targeting the ErbB pathway in acute myeloid leukemia Driving CAR T-cells forward Identification and targeting leukemia stem cells: The path to the cure for acute myeloid leukemia.Hematopoietic stem cell transplantation-50 years of evolution and future perspectives.Anti-CD33 chimeric antigen receptor targeting of acute myeloid leukemia.T cells expressing CD123 chimeric antigen receptors for treatment of acute myeloid leukemia.Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies.Targeting CD123 in acute myeloid leukemia using a T-cell-directed dual-affinity retargeting platform Cytokine-induced killer cells efficiently kill stem-like cancer cells of nasopharyngeal carcinoma via the NKG2D-ligands recognition Immunotherapy in pediatric malignancies: current status and future perspectives Advanced targeted, cell and gene-therapy approaches for pediatric hematological malignancies: results and future perspectives The novel structure make LDM effectively remove CD123+ AML stem cells in combination with interleukin 3.High-affinity FRβ-specific CAR T cells eradicate AML and normal myeloid lineage without HSC toxicity.Unexpected mechanisms of action for a cytokine receptor-blocking antibody.T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia.Design and development of therapies using chimeric antigen receptor-expressing T cells CAR therapy for hematological cancers: can success seen in the treatment of B-cell acute lymphoblastic leukemia be applied to other hematological malignancies?Immunotherapy of acute leukemia by chimeric antigen receptor-modified lymphocytes using an improved Sleeping Beauty transposon platform.Chimaeric antigen receptor T-cell therapy for tumour immunotherapy.Understanding of leukemic stem cells and their clinical implications.Molecular therapeutic approaches for pediatric acute myeloid leukemia.Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells.Antibody-modified T cells: CARs take the front seat for hematologic malignancies.Emerging immunotherapies in older adults with acute myeloid leukemia.Antibody therapy for acute myeloid leukaemia.Adoptive immunotherapy with genetically modified lymphocytes in allogeneic stem cell transplantation.Adoptive immunotherapy for cancer or viruses.CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies.

P2860

Q26774678-35AF5BBB-4E02-4312-936B-EC5EF3BA1970 Q26781328-C456E776-2932-4DCC-B3D3-2DE6B71057B8 Q26795540-FB42706A-8766-4639-BAA8-F2C135A70962 Q27311035-4E0030A3-8BA3-4AB9-8317-16DD11928E14 Q28069889-1AAB4636-339B-4DFD-8579-30E9B43E4814 Q28075654-491B59EC-432D-499A-B232-BD78B47E1DCD Q28554677-F8FCA409-94CE-4942-84FB-558F036AC399 Q30244186-2C3EF3D2-E0A2-4386-B17D-448F69BE8D3C Q30637447-3A2131F2-13EF-496E-94EA-366F13CC6065 Q33415505-31C8DBF2-20EC-42DC-94BC-8FD5DB536EE9 Q33578792-669B14C3-39FF-4287-9C3E-6C18239BD1A6 Q33884816-A91715C7-7519-49EC-954E-DB5BD2ECAB8D Q33982491-297542FC-8DE2-473F-863E-D3C4CB1F4470 Q34046505-BF3CAF25-32E2-423A-865E-9CC3678405C8 Q34232877-37ED95B4-2D4A-43D1-A2B8-422F49535C7D Q34463419-1E371ACA-9C01-4DFE-8608-3A010F81DE21 Q35146288-536B2B74-CF38-44AB-918B-E5F78849E79F Q36219592-9D7BEEA1-4DDC-4FC7-B6DD-906E72B81F4F Q36386891-8D133850-6649-4D47-945B-941C0D0F069C Q36443107-D48B134D-4C9A-462F-96F2-B5B43FA22EDE Q36544290-E23A446B-9E9A-4254-B608-4575F713D19F Q36691818-18D9DFB1-715E-4747-9A8A-1D163C0FC747 Q36804215-FFD9172C-661E-4CE7-A739-5C08BC9B07CA Q36838862-D98687CE-8C17-4834-9E17-84CAD040D0BC Q36957716-44216374-3278-4CF3-BDA0-84ED251293A9 Q36997749-3DF2A735-C8DD-40B0-8B62-5AE90C9215FA Q37272020-58E47ECF-5891-45BC-A054-0D33217F6FA5 Q37418289-28EE892F-87BF-4F87-B154-C226449EDCA2 Q37587956-D9BC43AE-FD56-42EB-B6A3-A3B03BF41A73 Q37588329-B74C4B84-E081-409E-8A4D-757A6BAE372D Q37609801-27CA7D8C-652B-4CBA-B157-BD9C4EDBA405 Q37616010-C028B02C-C223-4097-8C29-0D2B21FF1595 Q37643136-B0B7EA2F-4999-45FA-BA6C-A155DF8AFA00 Q37697847-C962B006-1632-4B16-B9DF-EC4565D6254F Q37723469-CBB7BBFB-D078-432A-B93B-5870AA8E814F Q38075407-80C75A7F-119A-4C6A-AED8-ACE6AC1E4AFA Q38169814-52D6ECCC-93B9-4F2C-B951-6B9EB0E06222 Q38170501-705633E1-BE61-457A-98E5-9042D8C96E8F Q38178359-1490E005-E255-4C66-9100-6EA822348530 Q38186870-258F32D6-0537-4B22-B9B5-4B3E8526E2F5

P2860

Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor.

http://www.wikidata.org/entity/Q34329186

description

2013 nî lūn-bûn

@nan

2013 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Targeting of acute myeloid leu ...... fic chimeric antigen receptor.

@ast

Targeting of acute myeloid leu ...... fic chimeric antigen receptor.

@en

Targeting of acute myeloid leu ...... fic chimeric antigen receptor.

@nl

type

label

Targeting of acute myeloid leu ...... fic chimeric antigen receptor.

@ast

Targeting of acute myeloid leu ...... fic chimeric antigen receptor.

@en

Targeting of acute myeloid leu ...... fic chimeric antigen receptor.

@nl

prefLabel

Targeting of acute myeloid leu ...... fic chimeric antigen receptor.

@ast

Targeting of acute myeloid leu ...... fic chimeric antigen receptor.

@en

Targeting of acute myeloid leu ...... fic chimeric antigen receptor.

@nl

P1433

Q34329186-1A2D214C-2157-44B7-B976-9D2ADBA77A8D

P1476

Q34329186-D0E915E0-331A-44A3-8BAA-AFFCD6C8CA00

P2093

Q34329186-251530A3-C5E5-44A8-BBBD-FA49F3B65CE2

Q34329186-595617C2-D99B-4E27-A4B1-C9FA8044D399

Q34329186-6FB9BA8A-6A29-4905-803B-8E0DFAFA6FC5

Q34329186-79483858-0FFE-416D-B403-D5FC122BAA33

Q34329186-7D2FBDB0-F974-41DD-A9E9-7295B8E95AC2

Q34329186-8134985A-C727-43C5-81DF-B9F18801F5B6

Q34329186-8C2B2121-0C57-49A7-81FF-49CBB324170D

Q34329186-8C3CBD90-3CD6-45B3-80FB-A49463BEBF7B

Q34329186-CF8FEC1E-EB86-401E-B56E-92F830848520

P2860

Q34329186-06C4B0B3-1F50-4366-9F73-1A989C6BB079

Q34329186-06F2D4E4-8C94-4AEC-A360-EAB7C218F1A4

Q34329186-0BA1DC49-D3E7-476C-A1DA-065FDA9818E9

Q34329186-0D2F6812-2C00-459E-B264-7765A523038C

Q34329186-1C130216-163C-45FC-B362-078E6A96C5E8

Q34329186-1F601DE4-9EAA-4977-B026-61A4F6AE2620

Q34329186-280121C5-D478-4B30-A31D-0C25373A6700

Q34329186-2FCEA094-4A95-4BAE-A658-FF9A792FAD36

Q34329186-37077891-8D74-4F6C-827D-CBC148DFCCFE

Q34329186-3769A198-2565-4FC8-92EA-BFC5AC55FD7F

P304

Q34329186-CFE61C36-730A-4F2A-A7A8-B09E1FF296AD

P31

Q34329186-628F57DF-CDF4-4480-A2C4-546986341024

P356

Q34329186-88105145-864F-472E-A2DE-76D20F331DCE

P407

Q34329186-317FAAD9-D71F-416A-B46E-3226D61EC8E1

P433

Q34329186-CD960B45-DCEE-4DAA-9457-2DB3F56ED787

P478

Q34329186-DA34BEA3-D9CE-4B07-88FE-189CE735A9F7

P50

Q34329186-0F9E8CBD-8FC9-47F2-994C-89935D0EEEE5

Q34329186-61468054-D4A8-4049-9986-EC6D66D3AB34

Q34329186-AA4A54A3-43B5-4EA6-9C3E-960EED229D96

P577

Q34329186-6368F864-097B-4381-A668-B08C988F65C9

P5875

Q34329186-3F28F59D-5DE0-42ED-B607-BA0FE980C50C

P698

Q34329186-EA312416-0B88-4A46-9AA9-4A3F0AC7781A

P921

Q34329186-2E4EA888-322F-4DFF-9FA1-1FCAFEFC9911

P356

P1433

British Journal of Haematology

P1476

Targeting of acute myeloid leu ...... ific chimeric antigen receptor

@en

P2093

Andrea Biondi

http://www.w3.org/2001/XMLSchema#string

Dominique Bonnet

http://www.w3.org/2001/XMLSchema#string

Elisabetta Cribioli

http://www.w3.org/2001/XMLSchema#string

Ettore Biagi

http://www.w3.org/2001/XMLSchema#string

Francesca Maltese

http://www.w3.org/2001/XMLSchema#string

Greta M P Giordano Attianese

http://www.w3.org/2001/XMLSchema#string

Irene Pizzitola

http://www.w3.org/2001/XMLSchema#string

Stefania Galimberti

http://www.w3.org/2001/XMLSchema#string

Virna Marin

http://www.w3.org/2001/XMLSchema#string

P2860

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

Suicide gene therapy to increase the safety of chimeric antigen receptor-redirected T lymphocytes

Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell

A cell initiating human acute myeloid leukaemia after transplantation into SCID mice

The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells

Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells

Signal transduction, cell cycle regulatory, and anti-apoptotic pathways regulated by IL-3 in hematopoietic cells: possible sites for intervention with anti-neoplastic drugs

Inducible apoptosis as a safety switch for adoptive cell therapy

Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2

Novel conjugates of single-chain Fv antibody fragments specific for stem cell antigen CD123 mediate potent death of acute myeloid leukaemia cells.

P304

389-401

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/BJH.12282

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

161

http://www.w3.org/2001/XMLSchema#string

P50

Sarah Tettamanti

Chiara F Magnani

P577

2013-02-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

235713843

http://www.w3.org/2001/XMLSchema#string

P698

23432359

http://www.w3.org/2001/XMLSchema#string

P921